Related Experiment Video
Updated: Aug 16, 2026
Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
Rapid polymerase chain reaction-based detection of epidermal growth factor receptor gene mutations in lung
Qiulu Pan1, William Pao, Marc Ladanyi
1Department of Pathology, Memorial Sloan-Kettering Cancer Center, 1275 York Ave., New York, NY 10021, USA.
Abstract:
Somatic mutations in the tyrosine kinase domain of the epidermal growth factor receptor (EGFR) gene are present in lung adenocarcinomas that respond to the EGFR inhibitors gefitinib and erlotinib. Two types of mutations account for approximately 90% of mutated cases: short in-frame deletions in exon 19 and a specific point mutation in exon 21 at codon 858 (L858R). Screening for these mutations has been based mainly on direct sequencing. We report here the development and validation of polymerase chain reaction-based assays for these two predominant types of EGFR mutations. The assay for exon 19 mutations is based on length analysis of fluorescently labeled polymerase chain reaction products, and the assay for the exon 21 L858R mutation is based on a new Sau96I restriction site created by this mutation. Using serial dilutions of DNAs from lung cancer cell lines harboring either exon 19 or 21 mutations, we detected these mutations in the presence of up to approximately 90% normal DNA. In a test set of 39 lung cancer samples, direct sequencing detected mutations in 25 cases whereas our assays were positive in 29 cases, including 4 cases in which mutations were not apparent by sequencing. These assays offer higher sensitivity and ease of scoring and eliminate the need for sequencing, providing a robust and accessible approach to the rapid identification of most lung cancer patients likely to respond to EGFR inhibitors.
Insights
New PCR-based assays detect common epidermal growth factor receptor (EGFR) mutations in lung adenocarcinoma. These sensitive methods identify patients likely to respond to EGFR inhibitors, improving targeted therapy selection.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Somatic mutations in the epidermal growth factor receptor (EGFR) gene are key drivers in lung adenocarcinomas.
- Specific mutations, including exon 19 deletions and the L858R point mutation, predict response to EGFR inhibitors like gefitinib and erlotinib.
- Current screening relies on direct sequencing, which may lack sensitivity for detecting these critical mutations.
Purpose of the Study:
- To develop and validate novel polymerase chain reaction (PCR)-based assays for detecting the two most common EGFR mutations (exon 19 deletions and exon 21 L858R).
- To enhance the sensitivity and accessibility of mutation screening for identifying lung cancer patients eligible for EGFR-targeted therapies.
Main Methods:
- Development of a PCR assay for exon 19 mutations utilizing length analysis of fluorescently labeled products.
- Creation of a PCR assay for the exon 21 L858R mutation based on a novel Sau96I restriction site.
- Validation using serial dilutions of known mutant DNA and testing on a set of 39 lung cancer patient samples.
Main Results:
- The developed assays demonstrated high sensitivity, detecting mutations in the presence of up to 90% normal DNA.
- Compared to direct sequencing, the PCR assays identified more mutations (29 vs. 25 cases), including 4 missed by sequencing.
- The assays proved robust and easy to score, eliminating the need for sequencing.
Conclusions:
- The novel PCR-based assays provide a more sensitive, rapid, and accessible method for identifying common EGFR mutations in lung adenocarcinoma.
- These assays facilitate the identification of patients likely to benefit from EGFR inhibitor therapy, optimizing treatment strategies.
Related Concept Videos
02:38Mitogens and the Cell Cycle
01:32PCR - Polymerase Chain Reaction